Treats Human Immunodeficiency Virus (HIV-1) infection. ANDA 77267, held by Aurobindo Pharma. Zidovudine.
As of Nov 21, 2026, ANDA 77267 (Zidovudine), held by Aurobindo Pharma, was first approved by FDA on Sep 19, 2005, with 13 approved supplements and 0 published complete response letters.
Zidovudine tablets are a nucleoside analogue reverse transcriptase inhibitor indicated for: Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. Prevention of maternal-fetal HIV-1 transmission. 1.1 Treatment of HIV-1 Zidovudine tablets, a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 1.2 Prevention of Maternal-Fetal HIV-1 Transmission Zidovudine tablets are indicated for the prevention of maternal-fetal HIV-1 transmission.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2005 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Zidovudine300MG · tablet;oral | Zidovudine | Rx |
| Feb 10, 2020 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 10, 2020 | Supplement 18Labeling · Standard review | Approved | None posted |
| Feb 10, 2020 | Supplement 19Labeling · Standard review | Approved | None posted |
| Feb 10, 2020 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jun 26, 2015 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 30, 2012 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 28, 2012 | Supplement 12Labeling | Approved | None posted |
| May 19, 2011 | Supplement 10Manufacturing | Approved | None posted |
| Aug 24, 2010 | Supplement 11Labeling | Approved | None posted |
| Jun 14, 2010 | Supplement 9Labeling | Approved | None posted |
| May 8, 2009 | Supplement 8Labeling | Approved | None posted |
| Jun 9, 2008 | Supplement 6Labeling | Approved | None posted |
| Jun 19, 2007 | Supplement 3Labeling | Approved | None posted |
| Sep 19, 2005 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters